Neuberger Berman Group
CPRX

Neuberger Berman Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Neuberger Berman Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Buy
10,904
+829
+8% +$24.5K ﹤0.01% 1946
2026
Q1 		$249K Buy
10,075
+1,466
+17% +$34.9K ﹤0.01% 1917
2025
Q4 		$201K Sell
8,609
-185,445
-96% -$4.13M ﹤0.01% 1955
2025
Q3 		$3.82M Sell
194,054
-67,363
-26% -$1.39M ﹤0.01% 1021
2025
Q2 		$5.67M Buy
261,417
+56,098
+27% +$1.32M ﹤0.01% 932
2025
Q1 		$4.98M Buy
+205,319
New +$4.62M ﹤0.01% 932

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group's CPRX Position: Q2 2026 in Review

Neuberger Berman Group increased its Catalyst Pharmaceutical (CPRX) stake by 8.2% in Q2 2026, buying an estimated $24.5K and bringing the position to 10,904 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #1946.

Neuberger Berman Group first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.67M in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Neuberger Berman Group held 10,904 shares of Catalyst Pharmaceutical worth $343K as of Q2 2026.
  • Neuberger Berman Group bought 829 Catalyst Pharmaceutical shares in Q2 2026, an estimated $24.5K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1946 holding.
  • Neuberger Berman Group first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • Neuberger Berman Group's Catalyst Pharmaceutical position peaked at $5.67M in Q2 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.